Prime Medicine, Inc.
PRME
$1.27
-$0.07-5.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 146.02% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 146.02% | -- | -- | -- | -- |
| Cost of Revenue | 4.81% | -17.74% | -1.53% | 24.49% | -91.18% |
| Gross Profit | 34.30% | 23.01% | 2.04% | -24.49% | 93.09% |
| SG&A Expenses | 19.05% | -5.98% | 34.40% | 18.23% | 21.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.04% | -14.92% | 5.79% | 23.01% | 22.23% |
| Operating Income | -8.38% | 18.92% | -5.39% | -23.01% | -20.75% |
| Income Before Tax | -13.73% | 35.60% | -3.35% | -30.95% | -15.22% |
| Income Tax Expenses | -- | -- | -- | -532.26% | 166.34% |
| Earnings from Continuing Operations | -13.39% | 35.60% | -3.57% | -30.53% | -16.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.39% | 35.60% | -3.57% | -30.53% | -16.15% |
| EBIT | -8.38% | 18.92% | -5.39% | -23.01% | -20.75% |
| EBITDA | -7.80% | 20.25% | -4.88% | -22.64% | -20.64% |
| EPS Basic | 9.47% | 54.51% | 20.58% | 0.92% | 0.97% |
| Normalized Basic EPS | 14.22% | 44.11% | 19.39% | 6.33% | -7.15% |
| EPS Diluted | 9.47% | 54.51% | 20.58% | 0.92% | 0.97% |
| Normalized Diluted EPS | 14.22% | 44.11% | 19.39% | 6.33% | -7.15% |
| Average Basic Shares Outstanding | 25.29% | 41.59% | 30.40% | 31.75% | 17.29% |
| Average Diluted Shares Outstanding | 25.29% | 41.59% | 30.40% | 31.75% | 17.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |